OncLive TV

Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.

Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the ​phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.

Howard M. Ross, MD, discusses advances in recognizing, screening, and treating patients with colorectal cancer.

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.

Laura Spring, MD, discusses next steps of the phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

Jan Joseph Melenhorst, BSc, MS, PhD, discusses the persistence of CD4+ CAR T-cells in inducing remissions in patients with chronic lymphocytic leukemia.

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

Sam Klempner, MD, discusses the results of the ongoing phase 2a DisTinGuish trial in advanced gastroesophageal adenocarcinoma.

Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma.

Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.